Flecainide
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Flecainide: From Cardiac Arrhythmia (Atrial Fibrillation) to Stroke Disorder
One-Sentence Summary
Flecainide is a Class Ic sodium-channel-blocking antiarrhythmic, used clinically to control atrial fibrillation, atrial flutter, and other cardiac arrhythmias. The TxGNN model predicts it may be effective for Stroke Disorder, with 19 clinical trials and 20 publications identified, though most of this evidence addresses atrial fibrillation rhythm control rather than a direct anti-stroke effect. Evidence level is L2, but the link to stroke is mechanistically indirect and comes with a known cardiac safety history that warrants caution.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not established from Australian regulatory data (no ARTG licence on file); described in the supporting literature as a Class Ic antiarrhythmic for atrial fibrillation/flutter and other arrhythmias |
| Predicted New Indication | Stroke Disorder |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L2 |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (DrugBank MOA field is a data gap). Based on the supporting literature, flecainide is a Class Ic antiarrhythmic that blocks cardiac sodium channels, used to maintain sinus rhythm in patients with atrial fibrillation (AF), atrial flutter, and ventricular arrhythmias; its efficacy in rhythm control is well established.
Atrial fibrillation is a major cause of cardioembolic stroke. The rationale behind this TxGNN prediction is that by suppressing AF and maintaining sinus rhythm, flecainide may indirectly reduce embolic stroke risk — not through any direct cerebrovascular or antithrombotic action. This is reflected in the evidence itself: the EAST-AFNET 4 trial (NCT01288352) tested early rhythm-control therapy (including antiarrhythmic drugs such as flecainide) against usual care for prevention of AF-related cardiovascular complications, including stroke as part of a composite endpoint.
This mechanistic link should be treated cautiously. Flecainide carries a well-documented safety history from the CAST trial, where suppressing ventricular arrhythmias post-myocardial infarction with Class Ic agents increased mortality — meaning its use in structural heart disease or coronary artery disease requires careful risk-benefit assessment, and its proarrhythmic potential is not trivial. The model’s “stroke disorder” association most plausibly reflects proximity to AF/rhythm-control biology rather than a genuine, direct antithrombotic or neuroprotective effect.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT01288352 | Phase 4 | Completed | 2,789 | EAST-AFNET 4: early structured rhythm-control therapy (antiarrhythmics incl. flecainide + catheter ablation) vs usual care for prevention of AF-related complications, including stroke as part of a composite endpoint (Grade A relevance) |
| NCT01646281 | Phase 4 | Unknown | 70 | Direct flecainide study: effects of vernakalant and flecainide on atrial contractility in AF; reduced contractility post-cardioversion is linked to stroke risk, but the trial’s endpoint is cardiac function, not stroke |
| NCT00911508 | N/A | Completed | 2,204 | CABANA: catheter ablation vs antiarrhythmic drug therapy (flecainide a possible comparator) for AF; not powered specifically for stroke outcome |
| NCT05213104 | Phase 3 | Active, not recruiting | 186 | Direct flecainide study: assesses whether flecainide lowers atrial arrhythmia/tachycardia risk after PFO closure in cryptogenic stroke patients — closest direct link between flecainide and stroke-related pathology, results not yet available |
| NCT07405671 | Phase 4 | Not yet recruiting | 988 | Direct flecainide study: safety of flecainide vs standard rhythm-control drugs (sotalol/amiodarone) in AF patients with stable coronary artery disease |
| NCT00523978 | Phase 3 | Completed | 245 | STOP AF: cryoablation vs an AF drug (flecainide, propafenone, or sotalol) in patients with paroxysmal AF refractory to drug therapy |
| NCT05293080 | Phase 3 | Not yet recruiting | 1,746 | Tests whether early, comprehensive rhythm-control therapy prevents adverse cardiovascular outcomes in patients with acute ischaemic stroke and AF |
| NCT01447862 | Phase 4 | Completed | 101 | Vernakalant vs ibutilide for recent-onset AF conversion; does not use flecainide, disease-area relevance only |
| NCT07270848 | Phase 4 | Not yet recruiting | 1,898 | Dronedarone for early rhythm control in AF; does not use flecainide, disease-area relevance only |
| NCT02459574 | N/A | Completed | 321 | Ablation vs antiarrhythmic therapy for reducing hospital episodes from recurrent AF |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38702961 | 2024 | RCT (EAST-AFNET 4 follow-up) | Europace | Safety/efficacy of long-term sodium-channel-blocker (flecainide/propafenone) therapy for early rhythm control in AF |
| 25430048 | 2014 | Review/Guideline | BMJ Clinical Evidence | Overview of acute AF management and its association with increased stroke risk |
| 37109225 | 2023 | RCT | Journal of Clinical Medicine | Compares carvedilol vs flecainide for idiopathic PVCs from the ventricular outflow tract (cardiac, non-stroke endpoint) |
| 28496906 | 2013 | Cohort | Journal of Atrial Fibrillation | Real-world cohort comparing cardiovascular events, including stroke, across antiarrhythmics (dronedarone vs amiodarone and others) |
| 27159789 | 2016 | Review | Nature Reviews Disease Primers | Comprehensive AF review, noting stroke as a serious AF complication |
| 30067936 | 2018 | Guideline | Medical Journal of Australia | Australian national clinical guidelines for diagnosis and management of AF (directly relevant to the Australian practice context) |
| 39077579 | 2023 | Review | Reviews in Cardiovascular Medicine | Management of AF during pregnancy, including antiarrhythmic and anticoagulant risk-benefit considerations |
| 27884575 | 2017 | Case Report (safety) | The Journal of Emergency Medicine | Brugada ECG pattern unmasked by flecainide overdose in an AF patient |
| 40800559 | 2025 | Case Report (safety) | European Heart Journal Case Reports | Refractory ventricular tachycardia associated with flecainide use (“flecainide fallout”) |
| 35114252 | 2022 | Mechanistic study | Journal of Molecular and Cellular Cardiology | Biophysical basis for flecainide’s relative atrial selectivity and lower ventricular pro-arrhythmia rate in AF |
Australia Market Information
Currently no ARTG entries are recorded for flecainide in this evidence pack — flecainide is listed as not marketed in Australia in the underlying regulatory data source used to build this report.
Safety Considerations
Formal TGA-sourced warnings, contraindications, and drug-interaction data are not available in this evidence pack (regulatory PI could not be retrieved — flagged as a blocking data gap). However, the supporting literature surfaces safety signals worth noting for context:
- Proarrhythmic risk: Flecainide’s clinical reputation is shaped by the CAST trial finding that Class Ic agents increased mortality when used to suppress ventricular arrhythmias post-myocardial infarction, making structural/ischaemic heart disease a key risk factor to screen for.
- Sick sinus node caution: Class Ic sodium-channel blockade can suppress sinus node conduction; sinus node dysfunction is a recognised relative contraindication.
- Case-report signals: overdose-associated Brugada ECG pattern (PMID 27884575) and refractory ventricular tachycardia (PMID 40800559).
Please refer to the TGA-approved Product Information (PI) for authoritative safety information before any clinical use.
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted stroke benefit is mechanistically indirect (via AF rhythm control, not a direct anti-stroke effect), the drug is not currently marketed in Australia, and a blocking data gap exists for TGA/PI safety information — combined with flecainide’s known proarrhythmic history, this does not yet meet the bar to proceed.
To proceed, the following is needed:
- TGA-approved Product Information (warnings, contraindications, drug interactions)
- Confirmed mechanism of action detail (DrugBank MOA is currently a data gap)
- Clarification of whether AF-mediated stroke risk reduction offers meaningful benefit over established anticoagulation-based stroke prevention
- Route/dosage-form compatibility assessment for the Australian formulary, given the drug is not currently marketed
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.